Ted Love
About Ted W. Love, M.D.
Ted W. Love, M.D., 66, has served as an independent director of Structure Therapeutics (GPCR) since August 2023. He is a seasoned biopharma leader and former practicing physician, with prior CEO roles and senior R&D leadership across multiple companies. Dr. Love holds a B.A. in molecular biology (Haverford College) and an M.D. (Yale), completed an internal medicine residency and cardiology fellowship at Massachusetts General Hospital, and previously chaired Genentech’s Product Development Committee .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Global Blood Therapeutics, Inc. | President & Chief Executive Officer | Jun 2014 – Oct 2022 | Led company through acquisition by Pfizer; prior GPCR target expertise . |
| Onyx Pharmaceuticals, Inc. | EVP, Research & Development and Technical Operations | Feb 2010 – Aug 2012 | Oversaw late-stage development operations . |
| Nuvelo, Inc. | President, CEO & Chairman | 2001 – Jan 2009 | Corporate leadership through clinical programs . |
| Theravance, Inc. | Senior Vice President, Development | 1998 – 2001 | Advanced development portfolio . |
| Genentech, Inc. | Senior management, Medical Affairs & Product Development; Chair, Product Development Committee | ~6 years (prior to 1998) | Chaired Product Development Committee . |
| Massachusetts General Hospital | Consultant in Medicine, Department of Cardiology | Not specified | Clinical advisory experience . |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Gilead Sciences, Inc. (NASDAQ: GILD) | Director | Current | Large-cap biopharma board experience . |
| Royalty Pharma plc (NASDAQ: RPRX) | Director | Current | Royalty aggregator board experience . |
| Seagen, Inc. | Director | 2020 – 2023 | Oncology biopharma (acquired) . |
| Amicus Therapeutics, Inc. | Director | 2012 – 2020 | Rare diseases . |
| Global Blood Therapeutics, Inc. | Director | 2013 – 2022 | Hematology; company acquired by Pfizer . |
| Portola Pharmaceuticals, Inc. | Director | 2019 – 2020 | Acquired by Alexion Pharmaceuticals . |
Board Governance
- Independence: Board affirmatively determined Dr. Love is independent under Nasdaq standards; he is also independent for Compensation Committee membership .
- Committee assignments: Chair, Compensation Committee; member, Research & Development Committee; served on Audit Committee during 2024 (appointed June 2024) .
- Attendance and engagement: In 2024, the Board held 7 meetings (Audit 4; Compensation 4; R&D 1), and no director attended fewer than 75% of Board and applicable committee meetings; executive sessions of independent directors occur regularly .
- Compensation governance quality: Compensation Committee engages an independent consultant (Aon), maintains formal processes, and reviews peer benchmarking; no interlocks or insider participation on the Compensation Committee; committee charters and Corporate Governance Guidelines posted on the company website .
Fixed Compensation (Director)
| Item | FY 2024 Amount |
|---|---|
| Fees Earned or Paid in Cash (Dr. Love) | $68,750 |
Policy schedule (non-employee directors; amended March 15, 2024, and updated Jan 21, 2025):
- Annual cash retainer: $45,000; Non-executive Chair additional $179,000; committee membership retainers: Audit $10,000; Compensation $7,500; R&D $7,500; Nominating $5,000; committee chair retainers: Audit $20,000; Compensation $15,000; R&D $15,000; Nominating $10,000 (pre-March 15, 2024 rates were lower) .
- Cash retainers are prorated based on service start dates; policy updated in Jan 2025 sets director initial option grant value to $800,000 and annual option grant value to $400,000 with value-based sizing limits and 30-day average pricing methodology .
Performance Compensation (Director)
| Item | FY 2024 Amount / Terms |
|---|---|
| Option Awards (grant-date fair value) | $360,289 (Dr. Love) |
| Annual equity form | Share options (no RSUs for directors disclosed) |
| Initial option grant | 75,000 ordinary shares (25,000 ADSs), vesting in 36 equal monthly installments |
| Annual option grant | 37,500 ordinary shares (12,500 ADSs), vesting in 12 equal monthly installments |
| Change-in-control treatment | Director options vest in full upon change in control |
| Performance metrics tied to director equity | Not disclosed; director equity is time-based |
Other Directorships & Interlocks
| Company | Relationship to GPCR | Interlock/Conflict Notes |
|---|---|---|
| Gilead Sciences, Inc. | External board (Love) | No GPCR-related transactions disclosed; Nominating Committee oversees conflicts . |
| Royalty Pharma plc | External board (Love) | No GPCR-related transactions disclosed . |
| Seagen, Amicus, GBT, Portola (prior) | External boards (Love) | No related-party transactions with GPCR disclosed; prior affiliations noted . |
Expertise & Qualifications
- Clinical and scientific leadership: Former practicing cardiologist; extensive R&D and product development leadership, including chairing Genentech’s Product Development Committee .
- Executive management: Multi-company CEO/EVP roles with track records in clinical development and transactions .
- Education: B.A. in molecular biology (Haverford), M.D. (Yale), residency and cardiology fellowship (Massachusetts General Hospital) .
Equity Ownership
| Measure | Amount |
|---|---|
| Options outstanding (ordinary shares) as of 12/31/2024 | 108,594 |
| Options exercisable within 60 days of 4/17/2025 (ordinary shares) | 76,623 |
| Shares outstanding (ordinary shares) at record date 4/17/2025 | 172,610,249 |
| Beneficial ownership % (options exercisable/OS) | ~0.044% (76,623 ÷ 172,610,249) |
| Pledged shares | Prohibited by insider trading policy |
| Hedging | Prohibited (no derivatives, options, collars, exchange funds) |
Governance Assessment
- Strengths: Independent director; chairs Compensation Committee with independent consultant support and robust processes; no compensation committee interlocks; high meeting attendance; clawback policy in place; hedging/pledging prohibited; committee charters and governance guidelines disclosed .
- Shareholder signals: 2025 say-on-pay passed (115,026,066 for; 19,231,338 against), and shareholders preferred annual say-on-pay frequency (1-year) .
- Potential conflicts: No related-party transactions disclosed involving Dr. Love; prior related-person transactions involved a different director (Schrödinger) with immaterial thresholds per independence determinations .
- Compensation alignment: Director pay is cash plus time-based options; policy now value-based for option sizing; change-in-control full vesting is standard in biotech but increases sensitivity to M&A outcomes .
RED FLAGS: None disclosed specific to Dr. Love (no pledging, no related-party transactions, no attendance shortfalls). Continue monitoring external board roles (GILD, RPRX) for any future business ties with GPCR; Nominating Committee is mandated to assess conflicts .